Drug utilization of clarithromycin for gastrointestinal disease treatment

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 39

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

317

HTML

2151

Tables (1-4)

182

Sum=2650

Oct 21, 2008 (publication date) through Nov 5, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Oct 21, 2008; 14(39): 6065-6071
Published online Oct 21, 2008. doi: 10.3748/wjg.14.6065

Table 1 Details of prescriptions of the two clarithromycin products

	Clarithromycin
	Sustained-release	Immediate release
Total number of prescriptions	949	197
Number of prescriptions for alimentary disease	164	110
Mean age (range) yr	45.9 (18-82)
Male:Female	137:137
Number of prescriptions for anti-H pylori therapy	159	96
Triple therapy	151	83
PPI/Clarithromycin/Amoxicillin	43	58
PPI/Clarithromycin/Furazolidone	44	21
PPI/Clarithromycin/Levofloxacin	63	1
PPI/Clarithromycin/Metronidazole	1	1
PPI/Clarithromycin/Tinidazole	0	2
Quadruple therapy	5	6
PPI/Bismuth/Amoxicillin/Clarithromycin	0	2
PPI/Bismuth/ Furazolidone/Clarithromycin	1	3
PPI/Bismuth/Levofloxacin/Clarithromycin	4	1
Dual therapy	3	7
Clarithromycin/PPI	2	7
Clarithromycin/Ranitidine bismuth citrate	1	0

PPI: Proton pump inhibitor.

Citation: Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008; 14(39): 6065-6071
URL: https://www.wjgnet.com/1007-9327/full/v14/i39/6065.htm
DOI: https://dx.doi.org/10.3748/wjg.14.6065